Golimumab: A novel human anti-TNF-α monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis

Core Evidence

Volumn 4, Issue , 2009, Pages 159-170

  Kay, Jonathan ^a   Rahman, Mahboob U ^b,c  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b CENTOCOR INC   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Ankylosing spondylitis; Golimumab; Psoriatic arthritis; Rheumatoid arthritis; TNF inhibitors

Indexed keywords

ADALIMUMAB; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANKYLOSING SPONDYLITIS; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; DISEASE ACTIVITY; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; HEADACHE; HEALTH ECONOMICS; HUMAN; INJECTION SITE ERYTHEMA; LYMPHOMA; NAUSEA; NONHUMAN; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; TUBERCULOSIS;

EID: 78649645500     PISSN: 15551741     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Helmick CG, Felson DT, Lawrence RC, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 2008;58:15-25.
2. Gladman DD, Antoni C, Mease P, Clegg DO, Nash, P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64:ii14-ii17.
3. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000;343:1586-1593. (Pubitemid 32162981)
4. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54:26-37. (Pubitemid 43122183)
5. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial. Arthritis Rheum. 2008;58:S126-S135.
6. Brennan FM, Maini RN, Feldmann M. TNF alpha-a pivotal role in rheumatoid arthritis? Br J Rheumatol. 1992;31:293-298.
7. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med. 1999;130:478-486.
8. Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000;343:1594-1602.
9. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003;48:35-45. (Pubitemid 36091645)
10. Behm BW, Bickston SJ. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2008;1:CD006893.
11. van Vollenhoven R, Harju A, Brannemark S, Klareskog L. Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense. Ann Rheum Dis. 2003;62:1195-1198. (Pubitemid 37500626)
12. Furst DE, Breedveld FC, Kalden JR, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis. 2007;66(Suppl 3):iii2-iii22.
13. Shealy D, Cai A, Nesspor T, et al. Characterization of golimumab (CNTO 148), a novel monoclonal antibody specific for human TNFα [abstract]. Ann Rheumatic Dis. 2007;66:151.
14. Shealy DJ, Visvanathan S. Anti-TNF antibodies: lessons from the past, roadmap for the future. Handb Exp Pharmacol. 2008;(181):101-129.
15. Zhou H, Jang H, Fleischmann RM, et al. Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis. J Clin Pharmacol. 2007;47:383-396. (Pubitemid 46294717)
16. Keffer J, Probert L, Cazlaris H, et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. 1991;10:4025-4031. (Pubitemid 21905432)
17. Jorgesen JT, Romsing J, Rasmussen M, Moller-Sonnergaard J, Vang L, Masaeus L. Pain assessment of subcutaneous injections. Ann Pharmacother. 1996;30:729-732. (Pubitemid 26243913)
18. Kappelgaard AM, Bojesen A, Skydsgaard K, Sjogren I, Laursen T. Liquid growth hormone: preservatives and buffers. Horm Res. 2004;62(Suppl 3):98-103.
19. Xu Z, Hu C, Vu T, et al. Population pharmacokinetics of golimumab, an anti-tumor necrosis factor-alpha human monoclonal antibody, in patients with rheumatoid arthritis [abstract]. Ann Rheum Dis. 2008;67:627.
20. Kay J, Matteson EL, Dasgupta B, et al. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum. 2008;58:964-975. (Pubitemid 351563997)
21. Inman RD, Davis JC Jr, Heijde D, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum. 2008;58:3402-3412.
22. Emery P, Fleischmann R, Moreland L, et al. Golimumab, a new human anti-TNF-alpha monoclonal antibody, administered subcutaneously every 4 weeks in methotrexate-naïve patients with active rheumatoid arthritis: A randomized, double-blind, placebo-controlled, GO-BEFORE Study [abstract]. Ann Rheum Dis. 2008;67:179.
23. Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum. 2009;60:976-986.
24. Keystone EC, Genovese MC, Klareskog L, et al; GO-FORWARD Study. Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis. 2009;68:789-796.
25. Smolen JS, Kay J, Doyle MK, et al.; for the GO-AFTER study investigators. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet. 2009 Jun 26. [Epub ahead of print].
26. Kavanaugh A, Mack M, Beutler A, et al. Golimumab, a New, human, TNF alpha antibody administered subcutaneously every 4 weeks in psoriatic arthritis patients: 52-week efficacy and safety results of the randomized, placebo-controlled GO-REVEAL study [abstract]. Ann Rheum Dis. 2008;67:99.
27. St Clair EW, van der Heijde DM, Smolen JS, et al; Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 2004;50(11):3432-3443.
28. Mease P, Kavanaugh A, Livingston J, et al. Golimumab significantly improves physical function, health-related quality of Life, productivity, and reduces time lost from work for caregivers in patients with active psoriatic arthritis [abstract]. Ann Rheum Dis. 2008;67:572.
29. Gladman D, Gómez-Reino J, Mease P, et al. Golimumab, a new human TNF-alpha antibody, administered every 4 weeks as a subcutaneous injection In psoriatic arthritis: Nail, enthesitis, and dactylitis response in the randomized, placebo-controlled, GO-REVEAL study [abstract]. Ann Rheum Dis. 2008;67:526.
30. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27:361-368.
31. Deodhar A, Hsu B, Buchanan J, et al. Golimumab significantly improves sleep in patients with active ankylosing spondylitis: Results from the Phase 3 GO-RAISE Study [abstract]. Ann Rheum Dis. 2008;67:383.
32. Buchanan J, Gathany T, Hsu B, Parasuraman S. Improving functionality improves sleep in patients with active ankylosing spondylitis: Results from the GO-RAISE Study [abstract]. Ann Rheum Dis. 2008;67:646.
33. Parasurman S, Buchanan J, Hsu B, Gathany T. Is there a relationship between functionality and productivity in patients with active anky-losing spondylitis? Resullts from the GO-RAISE study [abstract]. Ann Rheum Dis. 2008;67:574.
34. Scott DL, Kingsley GH. Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med. 2006;355:704-712.
35. Turesson C, McClelland RL, Christianson TJ, Matteson EL. Severe extra-articular disease manifestations are associated with an increased risk of first ever cardiovascular events in patients with rheumatoid arthritis. Ann Rheum Dis. 2007;66:70-75. (Pubitemid 46049688)
36. Maradit-Kremers H, Crowson CS, Nicola PJ, et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum. 2005;52:402-411. (Pubitemid 40220344)
37. Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2005;52:722-732. (Pubitemid 40365093)
38. Kvien TK. Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics. 2004;22:1-12. (Pubitemid 38269929)
39. Keystone EC. Strategies to control disease in rheumatoid arthritis with tumor necrosis factor antagonists-an opportunity to improve outcomes. Nat Clin Pract Rheumatol. 2006;2:594-601. (Pubitemid 44650947)
40. Furst D, Buchanan J, Rahman M, et al. Golimumab, a new human anti-TNF-alpha monoclonal antibody administered subcutaneously every 4 weeks, improves anemia and well-being in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis [abstract]. Ann Rheum Dis. 2008;67:181.
41. Gartlehner G, Hansen RA, Jonas BL, Thieda P, Lohr KN. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol. 2006;33:2398-2408. (Pubitemid 46067817)
42. Askling J, Fored CM, Baecklund E, et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis. 2005;64:1414-1420. (Pubitemid 41623850)